|
Aug 1, 2012
By:
Jill Wechsler
Medical apps, e-submissions, counterfeit drugs, and imports tucked into fairly "clean" user-fee renewal legislation.
|
|
Jul 1, 2012
By:
Jill Wechsler
Comparative research documenting value and affordability is key to obtaining coverage for high-cost therapies. Jill Wechsler reports.
|
Jun 1, 2012
By:
Jill Wechsler
A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market.
|
May 9, 2012
By:
Jill Wechsler
Switching Rx drugs to OTC and adding comparative data could broaden access to treatment, writes Jill Wechsler.
|
Apr 1, 2012
By:
Jill Wechsler
Disclosure rules the day, as industry confronts demands to report supply problems, results of clinical trials, and payment to doctors.
|
Mar 1, 2012
By:
Jill Wechsler
FDA and industry are pushing user fees, while they struggle with curbs on communications.
|
|
Feb 10, 2012
By:
Jill Wechsler
After months of anticipation, FDA finally issued guidances last month that outlines its recommendations for developing and approving biosimilar therapies.
|
Feb 1, 2012
By:
Jill Wechsler
Will expanded markets and ACOs offset higher rebates, added fees, and closer scrutiny of marketing and prices?
|
Jan 1, 2012
By:
Jill Wechsler
Look for action in 2012 on drug access, shortages, innovation, and transparency.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
